image_pdfimage_print

Inaugurated the upgraded Tablet Section IDPL Gurgaon. Also present were Shri Hansram Ahir, MOS C & F, Shri Praveen Kumar, IDPL, Dr V.K Subburaj, Secretary Pharmaceuticals, & Dr G.N Singh, All India Drug Controller.

Synopsys of speeches made on the occasion…

* Ministry is working on ‘Make-In-India’ mantra and this Unit of IDPL is a step in that direction. He assured Government of India`s full support in enhancing the efficiency and productivity of the Public Sector Undertakings.
* providing affordable and good quality medicines to masses of the country is important and the Public Sector Undertakings have an important role to play as they are not driven by profit motive but also serve public interest and Public Sector Undertakings will not be sold. Instead, a model will be developed for leveraging their assets to make them financially sustainable.
* A Task Force will be set up soon to look into all these aspects. Ministry is working in close coordination with other concerned Departments of the Government of India and the State Governments as a Team India for attaining health security.
* Jan Aushadhi will be revamped soon & that Pharma Clusters, Pharma Parks and Medical Devices Parks are also a step in this direction.

* Government will provide support to IDPL in enhancing its production and its modernization so that it is able to regain its past glory.

* Government is taking policy initiatives so that more and more Indian Pharmaceutical companies become compliant to the WHO Quality Standards
* Drugs provided by IDPL and other Public Sector Undertakings will facilitate in smooth functioning of the Government’s programmes and help provide access of good quality medicines to the people.

** General Tablet section of IDPL, Gurgaon Plant has been upgraded at the cost of Rs.3 Crore as per “Revised Sch -M” requirement and GMP certificate has been obtained.

After Modernization, IDPL-Gurgaon plant will be able to launch new products in the field of Diabetes, Oncology, NSAIDS, Antibiotics-3rd Generation, Nephrology and Cardiology including other segments of lifestyle diseases at affordable price and will play a vital role in providing the medicines at reasonable rate for the common people.